Hila Barak

710 total citations
21 papers, 521 citations indexed

About

Hila Barak is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hila Barak has authored 21 papers receiving a total of 521 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hila Barak's work include Renal and related cancers (7 papers), Peptidase Inhibition and Analysis (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Hila Barak is often cited by papers focused on Renal and related cancers (7 papers), Peptidase Inhibition and Analysis (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Hila Barak collaborates with scholars based in United States, Switzerland and Israel. Hila Barak's co-authors include Raphael Kopan, Scott C. Boyle, Ram Reshef, Jelena Martinović, Christine Bôle‐Feysot, Marc Jeanpierre, David M. Ornitz, Sung‐Ho Huh, Mélanie Parisot and Patrick Nitschké and has published in prestigious journals such as Journal of Clinical Oncology, Development and Developmental Cell.

In The Last Decade

Hila Barak

21 papers receiving 510 citations

Peers

Hila Barak

PRM

GENET

PHEOH

PPCH

Yoshinobu Moritoki Japan

Mita M. Shah United States

Haruhito Kikuchi Japan

Jolanta E. Pitera United Kingdom

Jane Striegel United States

Dervla M. Connaughton United States

Yoshihisa Ohtawara Japan

Katja Berger Germany

Yang Xiang China

Albertien M. van Eerde Netherlands

Yoshinobu Moritoki Japan

Hila Barak

272 ×0.7

112 ×0.6

PRM

96 ×1.1

GENET

54 ×0.7

PHEOH

55 ×0.8

PPCH

Citations per year, relative to Hila Barak Hila Barak (= 1×) peers Yoshinobu Moritoki

Countries citing papers authored by Hila Barak

Since Specialization

Citations

This map shows the geographic impact of Hila Barak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hila Barak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hila Barak more than expected).

Fields of papers citing papers by Hila Barak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hila Barak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hila Barak. The network helps show where Hila Barak may publish in the future.

Co-authorship network of co-authors of Hila Barak

This figure shows the co-authorship network connecting the top 25 collaborators of Hila Barak. A scholar is included among the top collaborators of Hila Barak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hila Barak. Hila Barak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chung, Vincent, Angela Alistar, Ben George, et al.. (2020). SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma. Annals of Oncology. 31. S218–S218. 6 indexed citations

Ko, Andrew H., Jeeyun Lee, María Alsina, et al.. (2020). Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology. 38(15_suppl). 4540–4540. 7 indexed citations

Desai, Jayesh, Jeremy Kortmansky, Neil H. Segal, et al.. (2019). MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.. Journal of Clinical Oncology. 37(4_suppl). TPS467–TPS467. 12 indexed citations

Chau, Ian, Georg Martin Haag, Osama E. Rahma, et al.. (2018). MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types. Annals of Oncology. 29. viii439–viii440. 14 indexed citations

Johnson, Melissa L., Benjamin Solomon, Mark M. Awad, et al.. (2018). MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 36(15_suppl). TPS9105–TPS9105. 9 indexed citations

Manji, Gulam A., Johanna C. Bendell, Do‐Youn Oh, et al.. (2018). MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. Journal of Clinical Oncology. 36(4_suppl). TPS530–TPS530. 6 indexed citations

Oh, Do‐Youn, Salah‐Eddin Al‐Batran, Hyun Cheol Chung, et al.. (2018). MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.. Journal of Clinical Oncology. 36(15_suppl). TPS4134–TPS4134. 7 indexed citations

Liu, Xiaochun, Deyaa Adib, Hila Barak, Richard M. Goldberg, & Salim Yazji. (2015). Development of a phase Ib/IIa proof-of-concept study of imalumab (BAX69), a first-in-class anti-macrophage migration inhibitory factor (MIF) antibody, as the 3^rd or 4^th line treatment in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). TPS3633–TPS3633. 5 indexed citations

Barak, Hila, Ella Preger‐Ben Noon, & Ram Reshef. (2012). Comparative spatiotemporal analysis of Hox gene expression in early stages of intermediate mesoderm formation. Developmental Dynamics. 241(10). 1637–1649. 10 indexed citations

10.

Barak, Hila, Sung‐Ho Huh, Shuang Chen, et al.. (2012). FGF9 and FGF20 Maintain the Stemness of Nephron Progenitors in Mice and Man. Developmental Cell. 22(6). 1191–1207. 216 indexed citations

11.

Barak, Hila, Kameswaran Surendran, & Scott C. Boyle. (2012). The Role of Notch Signaling in Kidney Development and Disease. Advances in experimental medicine and biology. 727. 99–113. 20 indexed citations

12.

Barak, Hila & Scott C. Boyle. (2011). Organ Culture and Immunostaining of Mouse Embryonic Kidneys. Cold Spring Harbor Protocols. 2011(1). pdb.prot5558–pdb.prot5558. 27 indexed citations

13.

Noon, Ella Preger‐Ben, Hila Barak, Noga Guttmann‐Raviv, & Ram Reshef. (2009). Interplay between activin and Hox genes determines the formation of the kidney morphogenetic field. Development. 136(12). 1995–2004. 38 indexed citations

14.

Surendran, Kameswaran, Scott Boyle, Hila Barak, et al.. (2009). The contribution of Notch1 to nephron segmentation in the developing kidney is revealed in a sensitized Notch2 background and can be augmented by reducing Mint dosage. Developmental Biology. 337(2). 386–395. 61 indexed citations

15.

Barak, Hila, et al.. (2005). Cell fate specification along the anterior–posterior axis of the intermediate mesoderm. Developmental Dynamics. 232(4). 901–914. 23 indexed citations

16.

Malachi, T., et al.. (1993). Red blood cell calcium level is elevated in women: enhanced calcium influx by estrogens.. PubMed. 121(3). 486–92. 3 indexed citations

17.

Gafter, Uzi, T. Malachi, Hila Barak, & J. Levi. (1990). Red blood cell calcium level in chronic renal failure: effect of continuous ambulatory peritoneal dialysis.. PubMed. 116(3). 386–92. 15 indexed citations

18.

Barak, Hila, et al.. (1990). Effect of verapamil on intestinal absorption of calcium in the rat.. PubMed. 16(6). 391–4. 4 indexed citations

19.

Malachi, T., et al.. (1989). Red blood cell calcium homeostasis in patients with end-stage renal disease.. PubMed. 114(3). 222–31. 31 indexed citations

20.

Barak, Hila. (1986). A lower bound on the integral of the nonlinear filtering error. Systems & Control Letters. 7(2). 109–116. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact